Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.94 |
| ▸ | CA4 | P22748 | 2/20 | 0.94 |
| ▸ | CA1 | P00915 | 14/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL16115635 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL823 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL29175054 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL28946409 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL29053363 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL27711371 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL431405 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL6123440 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL5865919 | 0.94 | CA2 (0.94) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL9279060 | 0.94 | CA2 (0.94) | CA2CA4CA1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022051316-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A SGLT-2 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051319-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A DPP-4 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051318-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A THYROID RECEPTOR BETA AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| EP-3345594-B1 | SOLUBILIZED FLAVONOID COMPOSITION | TECH INVESTMENTS LC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2012054090-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS | API GENESIS, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20080066739-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | disclosed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | disclosed |
| US-20030078517-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | disclosed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | disclosed |
| US-6350594-B1 | A METHOD USING CULTURED PLANT CELL GUMS PRODUCED FROM GUM-SECRETING CELLS OF VASCULAR PLANTS IN A VARIETY OF FOOD, DRUGS, VETERINARY, COSMETICS AND INDUSTRY | BIO POLYMERS PTY. LTD. (AU) | 2002-02-26 | — | — | US | disclosed |
| US-6271001-B1 | A SECRETED CULTURED PLANT GUM OF THE AIZOACEAE FAMILY; FOR EMULSIFYING/VISCOSIFYING/GELLING/THICKENING/FLOCCULATING AGENTS; FILM-FORMING/SIZING/COATING AGENTS, LUBRICANTS, COAGULANTS, FOOD, VETERINARY, COSMETIC, DRUG INDUSTRY | BIO POLYMERS PTY. LTD. (AU) | 2001-08-07 | — | — | US | disclosed |
| WO-1999057299-A1 | CULTURED PLANT CELL GUMS OF AIZOACEAE: FOOD, PHARMACEUTICAL, COSMETIC AND INDUSTRIAL APPLICATIONS OF CULTURED PLANT CELL GUMS OF AIZOACEAE AND OTHER PLANT FAMILIES | ALBRIGHT & WILSON (AUSTRALIA) LIMITED (AU) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CA2 2149/4885CA4 1858/4885CA1 1475/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CA2 2149/4885CA4 1858/4885CA1 1475/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CA2 2149/4885CA4 1858/4885CA1 1475/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CA2 2149/4885CA4 1858/4885CA1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.